ArticleMolecular genetics & genomic medicine2025
A Novel Intronic Mutation in MBD5 Results in Autosomal Dominant Intellectual Disability Type 1 due to Abnormal Splicing.
Article in Molecular genetics & genomic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Familial p.(Ala73Thr) Variant inClinical case reports · 2026Article
- A Novel Intronic Mutation in MBD5 Results in Autosomal Dominant Intellectual Disability Type 1 due to Abnormal Splicing.Molecular genetics & genomic medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWe identified a novel variant in MBD5 located within intron 6: c.114-13A>G (NM_018328.5) in a family with a patient presenting intellectual disability. This variant is hypothesized to be the etiological agent underlying the patient's condition.
methodsWe conducted an analysis of mRNA splicing within the patient and their relatives' blood samples via reverse transcription polymerase chain reaction (RT-PCR) to assess intronic mRNA splicing. Additionally, we employed a minigene vector construction approach to verify in vitro the splicing of mRNA containing the mutated fragment. Protein structure prediction analysis of the aberrant mRNA was performed using PyMOL software.
resultsThe patient harbors a novel mutation in the MBD5 gene: c.114-13A>G. Analysis of the patient's blood sample revealed the presence of aberrantly sized mRNA molecules. Utilizing a minigene approach, we discovered that this mutation results in the generation of two types of abnormally sized mRNAs. The first type of abnormal splicing leads to a 12-base pair retention at the 3' end of intron 6, and the second type of abnormal splicing causes exon 7 skipping.
conclusionIn accordance with the "Standards and Guidelines for the Interpretation of Sequence Variants" established by the American College of Medical Genetics and Genomics (ACMG), the novel mutation c.114-13A>G in the MBD5 gene meets the criteria for PS2 (the variant is de novo and not inherited from either parent) and PS3 (the variant affects mRNA splicing, resulting in aberrant transcripts). We propose that the c.114-13A>G variant, located within intron 6 of the MBD5 gene, is pathogenic. This discovery not only expands the repository of pathogenic variants for MBD5 but also provides additional insights into intronic mutations of the MBD5 gene, thereby offering significant information for the genetic diagnosis of Autosomal Dominant Intellectual Disability Type 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.